Heterobiaryl human immunodeficiency virus entry inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4481-4487

  Lu, Rong Jian ^a,d   Tucker, John A ^b   Pickens, Jason ^b   Ma, You An ^b   Zinevitch, Tatiana ^c   Kirichenko, Olga ^c   Konoplev, Vitalii ^c   Kuznetsova, Svetlana ^c   Sviridov, Sergey ^c   Brahmachary, Enugurthi ^b   Khasanov, Alisher ^b   Mikel, Charles ^b   Yang, Yang ^b   Liu, Changhui ^b   Wang, Jian ^b   Freel, Stephanie ^a   Fisher, Shelly ^a   Sullivan, Alana ^a   Zhou, Jiying ^a   Stanfield Oakley, Sherry ^a   Baker, Brian ^a   Sailstad, Jeff ^a   Greenberg, Michael ^a   Bolognesi, Dani ^a   Bray, Brian ^a   Koszalka, Barney ^a   Jeffs, Peter ^a   Jeffries, Cynthia ^b   Chucholowski, Alexander ^b   Sexton, Connie ^a   more..

^a Trimeris Inc   (United States)

^b ChemBridge Research Laboratories Inc   (United States)

^c ChemBridge Corporation   (United States)

^d Sequoia Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; GLYCOPROTEIN GP 120;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS ISOLATION;

ANIMALS; ANTI-HIV AGENTS; DRUG DISCOVERY; HIV; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 67650725979     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900330x     Document Type: Article

References (46)

1. (a) Hammer, S. M.; Saag, M. S.; Schechter, M.; Montaner, J. S.; Schooley, R. T.; Jacobsen, D. M.; Thompson, M. A.; Carpenter, C. C.; Fischl, M. A.; Gazzard, B. G.; Gatell, J. M.; Hirsch, M. S.; Katzenstein, D. A.; Richman, D. D.; Vella, S.; Yeni, P. G.; Volberding, P. A. International AIDS Society - USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA, J. Am. Med. Assoc. 2006, 296, 827-843.
2. (b) Gulick, R. M.; Ribaudo, H. J.; Shikuma, C. M.; Lalama, C.; Schackman, B. R.; Meyer, W. A.; Acosta, E. P.; Schouten, J.; Squires, K. E.; Pilcher, C. D.; Murphy, R. L.; Koletar, S. L.; Carlson, M.; Reichman, R. C.; Bastow, B.; Klingman, K. L.; Kuritzkes, D. R. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 2006, 296, 769-781.
3. (c) Rathbun, R. C.; Lockhart, S. M.; Stephens, J. R.; Current HIV treatment guidelines. An overview. Curr. Pharm. Des. 2006, 12, 1045-1063.
4. (a) Kumar, A.; Kilaru, K. R.; Forde, S.; Roach, T. C. Changing HIV infection-related mortality rate and causes of death among persons with HIV infection before and after the introduction of highly active antiretroviral therapy. J. Int. Assoc. Physicians AIDS Care 2006, 5, 109-114.
5. (b) Crum, N. F.; Riffenburgh, R. H.; Wegner, S.; Agan, B. K.; Tasker, S. A.; Spooner, K. M.; Armstrong, A. W.; Fraser, S.; Wallace, M. R. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) era. J. Acquir Immune Defic Syndr. 2006, 41, 194-200.
6. (c) Palella, F. J.; Baker, R. K.; Moorman, A. C.; Chmiel, J. S.; Wood, K. C.; Brooks, J. T.; Holmberg, S. D. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquired Immune Defic. Syndr. 2006, 43, 27-34.
7. (a) Roling, J.; Schmid, H.; Fischereder, M.; Draenert, R.; Goebel, F. D. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin. Infect. Dis. 2006, 42, 1488-1495.
8. (b) Wyatt, C. M.; Klotman, P. E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert. Opin. Drug Safety 2006, 5, 275-287.
9. (c) Haugaard, S. B. Toxic metabolic syndrome associated with HAART. Expert Opin. Drug Metab. Toxicol. 2006, 2, 429-445.
10. (a) Vaclavikova, J.; Weber, J.; Machala, L.; Reinis, M.; Linka, M.; Bruckova, M.; Vandasova, J.; Stankova, M.; Konvalinka, J. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Acta Virol. 2005, 49, 29-36.
11. (b) Liu, H.; Miller, L. G.; Hays, R. D.; Golin, C. E.; Wu, T.; Wenger, N. S.; Kaplan, A. H. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J. Acquired Immune Defic. Syndr. 2006, 41, 315-322.
12. (a) Briz, V.; Poveda, E; Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 2006, 57, 619-627.
13. (b) Rusconi, S.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. New advances in HIV entry inhibitors development. Curr. Drug Targets Infect. Disord. 2004, 4, 339-355.
14. (c) Shaheen, F.; Collman, R. G. Co-receptor antagonists as HIV-1 entry inhibitors. Curr. Opin. Infect. Dis. 2004, 17, 7-16.
15. (d) Markovic, I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr. Pharm. Des. 2006, 12, 1105-1119.
16. (a) Fatkenheuer, G.; Pozniak, A. L.; Johnson, M. A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A. I.; Saag, M. S.; Goebel, F. D.; Rockstroh, J. K.; Dezube, B. J.; Jenkins, T. M.; Medhurst, C.; Sullivan, J. F.; Ridgway, C.; Abel, S.; James, I. T.; Youle, M.; van der Ryst, E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11, 1170-1172.
17. (b) Greaves, W.; Landovitz, R.; Fatkenheuer, G.; Hoffmann, C.; Antunes, F; Angel, J.; Boparai, N.; Knepp, D.; Keung, A; Dunkle, L. Late Virologic Breakthrough in Treatment-Naive Patients on a Regimen of Combivir plus Vicriviroc. Presented at the 13th Conference on Reteroviruses and Opportunistic Infections, 2006; Abstract 161LB.
18. (c) Lalezari, J.; Thompson, M.; Kumar, P.; Piliero, P.; Davey, R.; Murtaugh, T.; Patterson, K.; Shachoy-Clark, A.; Adkison, K.; Demarest, J.; Sparks, S.; Fang, L.; Lou, Y.; Berrey, M.; Piscitelli, S. 873140, a Novel CCR5 Antagonist: Antiviral Activity and Safety during Short-Term Monotherapy in HIV-Infected Adults. Presented at the 44th Interscience Conference on Antiretroviral Agents and Chemotherapy, Washington, DC, 2004; Abstract H-1137b.
19. (a) Poveda, E.; Briz, V.; Soriano, V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 2005, 7, 139-147.
20. (b) Oldfield, V.; Keating, G. M.; Plosker, G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs 2005, 65, 1139-1160.
21. (c) Lazzarin, A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin. Pharmacother. 2005, 6, 453-464.
22. (d) Clotet, B.; Raffi, F.; Cooper, D.; Delfraissy, J. F.; Lazzarin, A.; Moyle, G.; Rockstroh, J.; Soriano, V.; Schapiro, J. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004, 18, 1137-1146.
23. Hanna, G.; Lalezari, J.; Hellinger, J.; Wohl, D.; Masterson, T.; Fiskel, W.; Kadow, J.; Lin, P.; Giordano, M.; Colonnol, R.; Grasela, D. Antiviral Activity, Safety, and Tolerability of a Novel, Oral Small-Molecule HIV-1 Attachment Inhibitor, BMS488043, in HIV-1-Infected Subjects. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, 2004; Abstract 141.
24. (a) Wang, H.-G. H.; Williams, R. E.; Lin, P.-F. A novel class of HIV inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr. Pharm. Des. 2004, 10, 1785-1793.
25. (b) Guo, Q.; Ho, H.-T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H.-G. H.; Rose, R. E.; Fang, H.; Scarnati, H. T.; Langley, D. R.; Meanwell, N. A.; Abraham, R.; Colonno, R. J.; Lin, P.-F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77, 10528-10536.
26. (a) Wang, T.; Zhang, Z.; Wallace, O. B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L. M.; Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B. S.; Gong, Y. F.; Riccardi, K.; Spicer, T. P.; Deminie, C.; Rose, R.; Wang, H. G.; Blair, W. S.; Shi, P. Y.; Lin, P. F.; Colonno, R. J.; Meanwell, N. A. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3- yl)oxoacetyl]-2-(R)-methylpiperazine (BMS378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46, 4236-4239.
27. (b) Yasutsugu, U.; Connolly, T.; Kadow, J.; Wang, T.; Meanwell, N.; et al. Prodrugs of Piperazine and Substituted Piperazine Antiviral Agents. U.S. Patent Appl. 2005/0209246A1, 2005.
28. (a) Lin, P.-F.; Blair, W.; Tao, W.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.-F.; Wang, H. H.-G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.-B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11013-11018.
29. (b) Guo, Q.; Ho, H.-T.; Dicker, I.; Fan, Li; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H. H.-G.; Rose, R. E.; Fang, H.; Scarnati, H. T.; Langley, D. R.; Meanwell, N. A.; Abraham, R.; Colonno, R. J. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77, 10528-10536.
30. (c) Kong, R.; Tan, J. J.; Ma, X. H; Chen, W.; Wang, C. X. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Biochim. Biophys. Acta 2006, 1764 (4), 766-767.
31. Wang, J.; Le, H.; Heredia, A.; Song, H.; Redfield, R.; Wang, L.-X. Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org. Biomol. Chem. 2005, 3 (9), 1781-1786.
32. Lu, R.-J.; Tucker, J. A.; Zinevitch, T.; Kirichenko, O.; Konoplev, V.; Kuznetsova, S.; Sviridov, S.; Pickens, J.; Tandel, S.; Brahmachary, E.; Yang, Y.; Wang, J.; Freel, S.; Fisher, S.; Sullivan, A.; Zhou, J.; Stanfield-Oakley, S.; Greenberg, M.; Bolognesi, D.; Bray, B.; Koszalka, B.; Jeffs, P.; Khasanov, A.; Ma, Y.-A.; Jeffries, C.; Liu, C.; Proskurina, T.; Zhu, T.; Chucholowski, A.; Li, R.; Sexton, C. Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the α-ketoamide group. J. Med. Chem. 2007, 50 (26), 6535-6544.
33. (a) Hu, Q. X.; Perkins, A. G.; Wang, Z.-X.; Connolly, S. M.; Peiper, S. C.; Greenberg, M. L. Evolution of the HIV-1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 2000, 74, 11858-11872.
34. (b) Mink, M.; Mosier, S. M.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Erickson, J.; Lambert, D.; Stanfield-Oakley, S. A.; Salgo, M.; Cammack, N.; Matthews, T.; Greenberg, M. L. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005, 79, 12447-12454.
35. Yang, Z; Zhang, Z; Meanwell, N. A.; Kadow, J. F.; Wang, T. A strategy for the Synthesis of aryl alpha-ketoamides based upon the acylation of anions derived from cyanomethylamines followed by oxidative cleavage. Org. Lett. 2002, 4 (7), 1103-1105.
36. Tanaka, A.; Terasawa, T.; Hagihara, H.; Sakuma, Y.; Ishibe, N.; Sawada, M; Takasugi, H.; Tanaka, H. Inhibitors of Acyl-CoA: cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroarylsubstituted benzyl)-N′-arylureas. J. Med. Chem. 1998, 13, 2390-2410.
37. Bombrun, A. N-Cinnamoyl Derivatives of Beta-Carboline. U.S. Patent 6,306,870B1, 2001.
38. Kajino M.; Hird, N. W.; Tarui, N.; Banno, H.; Kawano, Y.; Inatomi, N. Fused Quinoline Derivative and Use Thereof. WO2005105802 A1, 2005.
39. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters. J. Org. Chem. 1995, 60, 7508-7510.
40. (a) Stille, J. K. Palladium catalyzed coupling of organotin reagents with organic electrophiles. Pure Appl. Chem. 1985, 57, 1771-1780.
41. (b) Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
42. (a) Suzuki, A. Organoborates in new synthetic reactions. Acc. Chem. Res. 1982, 15, 178-184.
43. (b) Suzuki, A. Organoboron compounds in new synthetic reactions. Pure Appl. Chem. 1985, 57, 1749-1758.
44. Suzuki, A. Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides. Pure Appl. Chem. 1991, 63, 419-422.
45. S uzuki, A. New synthetic transformations via organoboron compounds. Pure Appl. Chem. 1994, 66, 213-222.
46. Bernd, R. Direct N-arylation of amides: an improvement of the Goldberg-reaction. Synthesis 1985, 9, 856-860.